• Day One Biopharmaceuticals Inc DAWN.OQ reported a quarterly adjusted loss of 29 cents​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -5 cents. The mean expectation of eight analysts for the quarter was for a loss of 36 cents per share. Wall Street expected results to range from -40 cents to -30 cents per share.

• Revenue rose 313.9% to $33.91 million from a year ago; analysts expected $35.30 million.

• Day One Biopharmaceuticals Inc's reported EPS for the quarter was a loss of 29 cents​.

• The company reported a quarterly loss of $30.32 million.

• Day One Biopharmaceuticals Inc shares had risen by 3.6% this quarter and lost 46.8% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 4.5% in the last three months.​

• In the last 30 days, two analysts negatively revised earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Day One Biopharmaceuticals Inc is $25.00, about 73.1% above its last closing price of $6.74

This summary was machine generated from LSEG data August 5 at 09:00 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)